SkinCure Oncology operates a turnkey model delivering image-guided superficial radiation therapy (IG‑SRT), partnering with dermatologists and Mohs surgeons to bring cancer-center level radiation treatments into physician offices. The company coordinates skin cancer treatment programs nationwide and provides comprehensive management services and operational staffing to dermatology practices. Founded in 2016 and headquartered in Burr Ridge, Illinois, SkinCure says it has treated more IG‑SRT patients than any other group worldwide. Company messaging and investor commentary highlight a first-mover advantage, strong unit economics, strong free cash flow characteristics, and strong revenue visibility. The firm positions IG‑SRT as a non-invasive alternative for treating non-melanoma skin cancers. Recent capital was intended to support a shareholder dividend and to capitalize the company for future growth.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2019